Lv6
3086 积分 2023-06-19 加入
P0848 Engineering and Development of a Novel Bispecific Antibody Targeting both TL1A and α4β7 for the Treatment of IBD
1个月前
已完结
Target identification and assessment in the era of AI
1个月前
已完结
Trends in target novelty in oncology R&D
1个月前
已完结
Immunotherapy combinations overcome resistance to bispecific T cell engager treatment in T cell–cold solid tumors
1个月前
已完结
High-affinity recombinant antibodies enable a sensitive MRGPRX2-specific ELISA for detecting allergic rhinitis and chronic spontaneous urticaria
1个月前
已完结
Restoring the potency of a neutralizing antibody via guided hypermutation with hyper-antibody editor HAE1
2个月前
已关闭
Engineering an antibody with picomolar affinity to DOTA chelates of multiple radionuclides for pretargeted radioimmunotherapy and imaging
3个月前
已完结
Abstract 1625: VHH nanobody-masked conditionally active CDH17 T cell engager for colorectal cancer
3个月前
已关闭
Therapeutic antibodies targeting G protein-coupled receptors
3个月前
已完结
Tumor-Specific Activation of an EGFR-Targeting Probody Enhances Therapeutic Index
4个月前
已完结
皖公网安备34019202002308
